Neuroendocrine Tumors: all 682 studies
Page 5 of 7. Open to participants first (163), then studies with results posted, then the rest; newest registration first within each.
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2
- Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNETCompletedNCT04385992Phase 2
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1
- Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive TumorsCompletedNCT04365023
- TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver MetsCompletedNCT04362436Phase 2
- Portal Vein Resection in Pancreatic Neuroendocrine TumoursStatus unknownNCT04336839
- Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)Approved for marketingNCT04334837
- PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic TreatmentStatus unknownNCT04331912
- Gallium-68 Labeled LM3 PET/CT in Neuroendocrine TumorsCompletedNCT04318561Phase 1/2
- Beta- Probe and Surgery in GEP NET: Evaluation of a New ProbeCompletedNCT04296149Phase 2
- Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell CarcinomaActive, not recruitingNCT04291885Phase 2
- Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
- Targeted Therapy and Avelumab in Merkel Cell CarcinomaActive, not recruitingNCT04261855Phase 1/2
- 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine TumorsTerminatedNCT04258592Phase 1
- 18F-AmBF3-TATE PET/CT for Imaging NET PatientsCompletedNCT04207762
- A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine TumorsStatus unknownNCT04207463Phase 2
- Microbiotic Analysis in Digestive Endocrine TumorsStatus unknownNCT04198402
- Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine CancerStatus unknownNCT04194125Phase 2
- Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine TumorStatus unknownNCT04154241Not applicable
- Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both ModalitiesStatus unknownNCT04152928Not applicable
- Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation OptimisationTerminatedNCT04140409Phase 4
- Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace RegionStatus unknownNCT04134832
- Octreotide LAR in the Induction of Immunologic Response in NENs PatientsCompletedNCT04129255Phase 2
- Image-Enhanced Endoscopy in the Gastrointestinal TractStatus unknownNCT04085211
- Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal CancersTerminatedNCT04077372Not applicable
- Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel FrequencyTerminatedNCT04073017Not applicable
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWithdrawnNCT04065165Phase 3
- Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced OsteomalaciaStatus unknownNCT04045834
- 68Ga-DOTATATE PET/CT in Neuroendocrine TumorStatus unknownNCT04041882Early Phase 1
- Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/GainWithdrawnNCT04034745
- Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR OverexpressionStatus unknownNCT04029428Phase 2
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Dynamic Whole Body Positron Emission Tomography/Computed Tomography ImagingStatus unknownNCT04017104
- Cryoablation of Bone Metastases From Endocrine TumorsTerminatedNCT03986593Not applicable
- Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mmStatus unknownNCT03982264Not applicable
- Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 TypeStatus unknownNCT03963193Phase 2
- PreOPerative Imaging of NeuroEndocrine TumorsStatus unknownNCT03958188
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
- Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging SequencesCompletedNCT03948841
- Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.TerminatedNCT03947762
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
- Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and AdolescentsWithdrawnNCT03923257Phase 1/2
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.CompletedNCT03910660Phase 1/2
- Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical PracticeWithdrawnNCT03895463
- Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine TumorsCompletedNCT03883776Phase 1
- DEBOXA for Inoperable NET Liver MetastasesStatus unknownNCT03881306Phase 1/2
- 68Ga-DOTATATE PET for Management of Neuroendocrine TumorsCompletedNCT03873870Not applicable
- Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive ExpressionCompletedNCT03870399Phase 2
- The Lyon Real World Evidence in Metastatic NeuroEndocrine TumoursStatus unknownNCT03863106
- Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the AppendixCompletedNCT03852693
- The Patient's Journey - the Time to Final Diagnosis in Patients With SiNETCompletedNCT03840720
- A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic BiomarkersStatus unknownNCT03840460
- Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine NeoplasmsCompletedNCT03834701Not applicable
- Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin AnalogsStatus unknownNCT03812939
- Pancreatectomy for NET: External Evaluation of WHO 2017 Grading SystemCompletedNCT03791346
- Neuroendocrine Tumors of Old Patients in the West of FranceStatus unknownNCT03749681
- Biomarker Study of Pancreatic Neuroendocrine TumoursStatus unknownNCT03741517
- A Phase 1 Study of ZSP1602 in Participants With Advanced Solid TumorsStatus unknownNCT03734913Phase 1
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
- Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver MetastasesTerminatedNCT03724409Early Phase 1
- Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETsCompletedNCT03722511Phase 2
- Post-Authorization Long-Term Safety Study of LUTATHERAActive, not recruitingNCT03691064
- Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs).Status unknownNCT03689231
- Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin AnalogueStatus unknownNCT03629847Phase 1/2
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruitingNCT03600233Phase 2
- The Management of Neuroendocrine Tumours: A Nutritional Viewpoint.CompletedNCT03592940
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2
- Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver MetastasesCompletedNCT03590119Phase 2/3
- DOTATOC PET/CT for Imaging NET PatientsActive, not recruitingNCT03583528
- Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine TumorsCompletedNCT03576040
- Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide AutogelCompletedNCT03562091
- A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine NeoplasmsStatus unknownNCT03511768Phase 1/2
- Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine TumorsActive, not recruitingNCT03498040
- Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03478358Phase 1
- Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NETTerminatedNCT03466216Phase 1
- A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3Status unknownNCT03457844Phase 2
- Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive TumorsActive, not recruitingNCT03454763Phase 2
- Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNENStatus unknownNCT03442959
- Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic NeoplasmsStatus unknownNCT03435770Not applicable
- Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN PatientsStatus unknownNCT03422029Phase 2
- Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions.Status unknownNCT03417843Not applicable
- A Study of XmAb®18087 in Subjects With NET and GISTCompletedNCT03411915Phase 1
- Psychosocial Screening for Neuroendocrine Tumor PatientsStatus unknownNCT03372356
- Gallium 68 Pentixafor in Patients With Neuroendocrine TumorsActive, not recruitingNCT03335670Early Phase 1
- Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer of the Colon, Stomach, Bile Ducts, Rectum, Pancreas or Lung, or Gastrointestinal Neuroendocrine TumoursTerminatedNCT03328065
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine TumorsStatus unknownNCT03308682Phase 1
- Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine NeoplasmsStatus unknownNCT03288597
- Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET PatientsCompletedNCT03288402Not applicable
- Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine TumorStatus unknownNCT03279601Phase 2
- Avelumab in G2-3 NETCompletedNCT03278379Phase 2
- PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105CompletedNCT03278275Phase 2
- PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2CompletedNCT03271281Phase 2
- Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in SpainCompletedNCT03220087
- MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating AgentsCompletedNCT03217097Not applicable
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine TumorStatus unknownNCT03204032Phase 2
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine TumorStatus unknownNCT03204019Phase 2
- Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine TumorCompletedNCT03197012Early Phase 1
- Proton Boost for Locally Advanced HEAD AND NECK TUMORSCompletedNCT03183271Not applicable
- Study of JS001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT03167853Phase 1
- Laser Tissue Welding - Distal Pancreatectomy Sealing StudyCompletedNCT03147768Phase 1